Evidence map›Paper›PMID 34930778›Full record

SynthesisJournal of neurology, neurosurgery, and psychiatry2022

Disrupted reward processing in Parkinson's disease and its relationship with dopamine state and neuropsychiatric syndromes: a systematic review and meta-analysis.

Harry Costello, Alex J Berry, Suzanne Reeves, Rimona S Weil, Eileen M Joyce, Robert Howard, Jonathan P Roiser

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of neurology, neurosurgery, and psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Management of Anxiety in Parkinson's Disease.Movement disorders clinical practice · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Prevalence and state-dependent patterns of non-motor fluctuations in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. New developments in imaging in ALS.Journal of neurology · 2025
    Review
  13. Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Harry CostelloInstitute of Cognitive Neuroscience, University College London, London, UK harry.costello@ucl.ac.uk.ORCID 0000-0003-4490-9219
Alex J BerryDivision of Psychiatry, University College London, London, UK.
Suzanne ReevesDivision of Psychiatry, University College London, London, UK.ORCID 0000-0001-8053-7024
Rimona S WeilInstitute of Neurology, University College London, London, UK.ORCID 0000-0002-5092-6325
Eileen M JoyceInstitute of Neurology, University College London, London, UK.ORCID 0000-0003-0469-2844
Robert HowardDivision of Psychiatry, University College London, London, UK.ORCID 0000-0002-3071-2338
Jonathan P RoiserInstitute of Cognitive Neuroscience, University College London, London, UK.ORCID 0000-0001-8269-1228

Funding

Wellcome Trust 175479Wellcome Trust 205167/Z/16/Z
6 · The paper itself

Abstract

backgroundNeuropsychiatric symptoms are common in Parkinson's disease (PD) and predict poorer outcomes. Reward processing dysfunction is a candidate mechanism for the development of psychiatric symptoms including depression and impulse control disorders (ICDs). We aimed to determine whether reward processing is impaired in PD and its relationship with neuropsychiatric syndromes and dopamine replacement therapy.

methodsThe Ovid MEDLINE/PubMed, Embase and PsycInfo databases were searched for articles published up to 5 November 2020. Studies reporting reward processing task performance by patients with PD and healthy controls were included. Summary statistics comparing reward processing between groups were converted to standardised mean difference (SMD) scores and meta-analysed using a random effects model.

resultsWe identified 55 studies containing 2578 participants (1638 PD and 940 healthy controls). Studies assessing three subcomponent categories of reward processing tasks were included: option valuation (n=12), reinforcement learning (n=37) and reward response vigour (n=6). Across all studies, patients with PD on medication exhibited a small-to-medium impairment versus healthy controls (SMD=0.34; 95% CI 0.14 to 0.53), with greater impairments observed off dopaminergic medication in within-subjects designs (SMD=0.43, 95% CI 0.29 to 0.57). Within-subjects subcomponent analysis revealed impaired processing off medication on option valuation (SMD=0.57, 95% CI 0.39 to 0.75) and reward response vigour (SMD=0.36, 95% CI 0.13 to 0.59) tasks. However, the opposite applied for reinforcement learning, which relative to healthy controls was impaired on-medication (SMD=0.45, 95% CI 0.25 to 0.65) but not off-medication (SMD=0.28, 95% CI -0.03 to 0.59). ICD was the only neuropsychiatric syndrome with sufficient studies (n=13) for meta-analysis, but no significant impairment was identified compared tonon-ICD patients (SMD=-0.02, 95% CI -0.43 to 0.39).

conclusionReward processing disruption in PD differs according to subcomponent and dopamine medication state, and warrants further study as a potential treatment target and mechanism underlying associated neuropsychiatric syndromes.

Indexed as

Disruptive, Impulse Control, and Conduct DisordersParkinson DiseaseDopamineDopamine AgentsHumansRewardSyndromeDopamineDopamine Agentscognitioncognitive neuropsychologyneuropsychiatryParkinson's disease

Identifiers

PMID34930778
PMCPMC9016258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.